Wednesday, January 11, 2023
Irwin Naturals Inc., is proud to announce it has signed a Letter of Intent entering into a partnership with Braxia Scientific Corp., a medical research company providing psychiatric, innovative ketamine and psilocybin treatments for mental health disorders, to launch Clinical Research Services across Irwin’s growing U.S. based network of clinics, Emergence.
The partnership will bring together Braxia’s expertise, track record of leadership in innovative mental health treatments and current comprehensive clinical research capabilities to 12 Emergence clinics in 5 US states. Under the terms of the LOI, Irwin will invest up to $2 million over the next 12 months to launch initial clinical research services beginning with at least 5 clinics in Florida.
Irwin and Braxia’s partnership will create a leading mental health focused clinical research platform designed to streamline and accelerate the process of in-human clinical development of new therapies, including seamless patient recruitment through to FDA application. The partnership will support multiple large and small pharmaceutical sponsors, innovative biotechnology companies, medical device companies, government and non-governmental institutions who seek to carry out the development of new therapies in the area of mental health in the US.
The mental health leadership of Braxia, through its globally recognized management and clinical development teams, will be a major accelerator and differentiator for Irwin’s network of clinics across the US. To date, Braxia’s CEO, Dr. Roger McIntyre continues to rank as the world’s foremost expert in depression research1. Dr. McIntyre and Dr. Joshua Rosenblat, Braxia Chief Medical and Science Officer have conducted dozens of national and international research studies involving thousands of patients living with depression. This is the type of value added services Emergence is looking to add to its growing network of clinics in the US.
Klee Irwin, CEO, Irwin Naturals commented, “We are extremely pleased to have reached a new milestone in the development of our clinics by establishing a strategic relationship with Dr. McIntyre and his research team. Having an outstanding reputation for scientific expertise, quality clinical research in depression and other mental health disorders areas that will enable us to further develop our US clinical footprint."
Dr. Roger McIntyre, CEO, Braxia Scientific, commented, “We are conducting a number of ongoing clinical trials and are currently receiving requests from various pharmaceutical sponsors to support international programs to develop novel therapies in mental health. We have been developing a plan to reach a broader market in the US and globally. This exciting partnership allows us to expand our expertise in an effective manner by leveraging the existing Irwin infrastructure deployed over a number of states in the U.S.”
The partnership is subject to execution of a final definitive legal agreement covering the above and other material terms of the relationship between Braxia and Irwin.